Publications

Mease et al. report that patients without radiographic progression through 2 years of secukinumab treatment had greater achievement of LDA states at Week 104 than patients with radiographic progression. This post hoc analysis by Mease et al. of the FUTURE 5 study evaluated the relationship between radiographic progression status at Week 104 and achievement of LDA or remission and identified demographics and clinical characteristics that were associated with radiographic progression status at Week 104.

Radiographic progression at Week 104 was associated with older age and elevated baseline hsCRP level, demonstrating the role of systemic inflammation and prolonged disease duration in structural joint damage. In contrast, radiographic non-progression was associated with lower baseline BMI and no prior TNF inhibitor exposure. These findings highlight the interconnected nature of radiographic progression, systemic inflammation and clinical outcomes, suggesting that early treatment with secukinumab may prevent progression of structural damage and improve long-term outcomes for patients with PsA.